Diabetes Care Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Diabetes Care stocks.

Diabetes Care Stocks Recent News

Date Stock Title
Nov 21 NVO Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Nov 21 NVO Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
Nov 20 NVO More companies covering weight loss drugs for their employees
Nov 20 NVO Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
Nov 20 NVO Is Novo Nordisk Stock a Buy Right Now?
Nov 20 NVO RFK Jr. Sparks New Worries About Obesity Drugs. Here’s What Investors Should Focus on Instead.
Nov 19 NVO Novo Nordisk semaglutide phase 3 trial for MASH meets primary endpoints
Nov 19 NVO Sector Update: Health Care Stocks Decline
Nov 19 NVO Novo Nordisk Unusual Options Activity For November 19
Nov 19 NVO Sector Update: Health Care Stocks Mixed Tuesday Afternoon
Nov 19 NVO Novo Erases 2024 Gain, Wiping Out $210 Billion in Value
Nov 19 NVO Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs
Nov 19 PRGO Perrigo Company: Great Combination Of Future Growth With A Low Valuation
Nov 19 NVO Employers Get Pressure to Pay for Drugs Like Wegovy
Nov 18 NVO RFK Jr.'s HHS nomination sparks concern over pharma stocks
Nov 18 NVO Novo Nordisk reportedly launches Wegovy in China
Nov 18 NVO How Robert F. Kennedy Jr. could impact the healthcare sector as secretary of health
Nov 18 NVO Market Chatter: Eli Lilly, Novo Nordisk Obesity Drugs Covered Mostly by Medicaid, Analysts Say
Nov 18 NVO Exclusive: Medicaid fuels US coverage of Novo, Lilly weight-loss drugs
Nov 16 NVO The weight-loss frenzy is making some pharma stocks much more volatile. Will the drama continue?
Diabetes Care

Diabetes Care is a monthly peer-reviewed medical journal published since 1978 by the American Diabetes Association. The journal covers research in the following five categories: 1) clinical care/education/nutrition/psychosocial research, 2) epidemiology/health services research, 3) emerging treatments and technologies, 4) pathophysiology/complications, and 5) cardiovascular and metabolic risk. The journal also publishes clinically relevant review articles, letters to the editor, and commentaries.According to the Journal Citation Reports, the journal has a 2017 impact factor of 13.397 ranking it fifth out of 138 journals in the category "Endocrinology & Metabolism."

Browse All Tags